| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
|
Ann Rheum Dis
|
2005
|
4.67
|
|
2
|
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
|
Ann Rheum Dis
|
2008
|
3.45
|
|
3
|
Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis.
|
Clin Exp Rheumatol
|
2014
|
2.06
|
|
4
|
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.
|
Ann Rheum Dis
|
2009
|
1.71
|
|
5
|
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
|
Ann Rheum Dis
|
2007
|
1.70
|
|
6
|
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
|
Ann Rheum Dis
|
2012
|
1.67
|
|
7
|
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
|
Ann Rheum Dis
|
2010
|
1.34
|
|
8
|
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
|
Ann Rheum Dis
|
2008
|
1.31
|
|
9
|
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
|
Ann Rheum Dis
|
2011
|
1.17
|
|
10
|
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
|
Br J Dermatol
|
2012
|
1.01
|
|
11
|
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.
|
Ann Rheum Dis
|
2013
|
0.91
|
|
12
|
The fibromyalgia conundrum.
|
Clin Exp Rheumatol
|
2010
|
0.79
|
|
13
|
The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2 years after onset.
|
Ann Intern Med
|
1995
|
0.79
|